Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $14 billion in the first nine months of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth was one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product. Ironically, Ozempic and Wegovy, like many of Novo Nordisk's other prod ...

整理 | GLP1减重宝典内容团队 诺和诺德公司宣布，加拿大卫生部已授予其重磅GLP-1类药物Wegovy（司美格鲁肽注射液）附条件上市许可，用于治疗伴有中度至重 度肝纤维化（F2–F3期）的非肝硬化性代谢相关脂肪性肝炎成人患者。这一决定标志着司美格鲁肽在肥胖与代谢疾病之外，正式向肝脏 疾病领域延伸其临床与监管边界。 加入专家库与我们深度讨论 「GLP-1俱乐部」覆盖数百位专业人士，构建了围绕GLP-1产业链上下游、覆盖多个板块的专家库，成为了业内顶尖专业人士获取行业真知灼见的首要选择。加入 专家库请添加下方「运营负责人」微信，并提供名片和必要的个人信息。 此次新适应症的获批，基于司美格鲁肽在全球III期ESSENCE临床试验中所显示出的安全性与疗效数据。临床结果显示，在试验设定的 观察周期内，与安慰剂组相比，接受司美格鲁肽治疗的患者在脂肪性肝炎改善以及肝纤维化程度减轻方面均取得统计学意义上的显著进 展，且整体安全性特征处于可接受范围之内。 从监管层面看，加拿大卫生部此次采取附条件批准路径，意味着该适应症仍需在后续研究中进一步验证长期疗效与安全性，但同时也反 映出在MASH这一尚无成熟药物治疗方案的领域，监管 ...

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

President Donald Trump on Friday unveiled a sweeping set of drug-pricing agreements with nine major pharmaceutical companies, presenting the initiative as a cornerstone of his effort to bring American medicine costs closer to those paid in Europe.The announcement marked a significant expansion of the administration’s pricing push, with Trump confirming that deals have now been struck with 14 of the 17 drugmakers he formally pressed in July to lower prices. Central to the strategy is the launch of a new dire ...

Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government’s Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche’s US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on.Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid p ...

US President Donald Trump on Friday (December 19) announced agreements with nine major pharmaceutical companies to sharply cut the prices of medicines sold through the government’s Medicaid program and to cash-paying consumers, marking his latest push to bring US drug costs in line with those in other wealthy nations.The deals were unveiled at a White House press conference, where Trump appeared alongside senior executives from the participating drugmakers.“We were subsidizing the entire world. We’re not do ...

​Novo Nordisk A/S (NYSE:NVO) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December 12, Novo Nordisk A/S (NYSE:NVO) announced receiving a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use for a higher dosage of Wegovy. ​The positive opinion is based on improved weight loss results of around 20.7% at 72 weeks in people without diabetes. Management noted that the STEP UP and STEP UP T2D clinical trial program showed that one in three ob ...

US President Donald Trump is expected to announce new agreements on Friday (December 19) aimed at lowering prescription drug prices, the White House said. The announcement is scheduled for 1 p.m. ET at the White House.AbbVie, Bristol Myers Squibb, Gilead Sciences, and Merck are among the major pharmaceutical companies expected to participate, Reuters reporting citing sources familiar with the matter.Swiss drugmakers Novartis and Roche are also reportedly part of the deals, according to Bloomberg News.Backgr ...

Key Takeaways Novo Nordisk submitted an NDA for CagriSema, a once-weekly injection for long-term weight control in adults.Novo Nordisk said CagriSema delivered up to 22.7% weight loss in REDEFINE 1 and 15.7% in REDEFINE 2.NVO is diversifying beyond semaglutide as GLP-1 competition and pricing pressure weigh on recent growth.Novo Nordisk (NVO) announced the submission of a new drug application (NDA) to the FDA, seeking approval for its next-generation once-weekly injection, CagriSema, to reduce excess body w ...

Scott Kaufman, aka Treading Softly, learned about investing firsthand from over a decade of financial sector experience. He is the lead analyst for Dividend Kings providing actionable insight into high quality dividend growing and undervalued opportunities. His focus is to see a bountiful harvest of cash dividends and strong capital gains, providing a robust total return.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...